ASMB News & Events

Reports Q1 revenue $8.21M, consensus $6.95M. "The first quarter reflected steady progress across our portfolio as we continue advancing our discovery and development programs," said Jason Okazaki, chief executive officer and president of Assembly Bio. "As we look ahead, we anticipate receiving Gilead's development plan and budget for the herpesvirus program and will evaluate our cost and profit share opt-in decision by mid-2026 while continuing to advance ABI-6250 toward Phase 2 in hepatitis delta virus by year-end."

Assembly Biosciences files $400M mixed securities shelf

H.C. Wainwright analyst Patrick Trucchio reiterates a Buy rating on Assembly Biosciences (ASMB) with a $50 price target after the company announced that Gilead (GILD) exercised its option to license both of Assembly's long-acting herpes simplex virus helicase-primase inhibitors being developed for the treatment of recurrent genital HSV infection. Gilead's exclusive license de-risks Assembly's novel antiviral pipeline, the analyst tells investors in a research note. H.C. Wainwright believes Gilead's opt-in "significantly de-risks the programs and provides Assembly with a strong financial foundation to execute across its pipeline of next-generation antivirals."